Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM11260C (Langlenatide) for weight loss in obese adults without diabetes
2013-004251-21Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Langlenatide arm with Placebo arm (2 arms). Primary endpoint: Change in body weight over 20 weeks. Started Dec 2013; status: completed.
02
Drugs
efpeglenatide
03
Conditions
obesity
Beyond the preview
Go deeper on 2013-004251-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004251-21.